Insider Transactions in Q3 2021 at Nektar Therapeutics (NKTR)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 22
2021
|
Jeffrey Robert Ajer Director |
SELL
Open market or private sale
|
Direct |
3,665
-10.13%
|
$62,305
$17.78 P/Share
|
|
Sep 22
2021
|
Jeffrey Robert Ajer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+21.99%
|
-
|
|
Sep 22
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
4,600
-1.62%
|
$78,200
$17.94 P/Share
|
|
Sep 22
2021
|
Robert Chess |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+3.46%
|
-
|
|
Sep 22
2021
|
Myriam Curet Director |
SELL
Open market or private sale
|
Direct |
3,665
-12.45%
|
$62,305
$17.78 P/Share
|
|
Sep 22
2021
|
Myriam Curet Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+25.73%
|
-
|
|
Sep 22
2021
|
Karin Eastham Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+22.92%
|
-
|
|
Sep 22
2021
|
R Scott Greer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+3.5%
|
-
|
|
Sep 22
2021
|
Roy A Whitfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+4.14%
|
-
|
|
Sep 16
2021
|
Roy A Whitfield Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+15.05%
|
$520,000
$13.8 P/Share
|
|
Sep 09
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
10,279
-3.61%
|
$164,464
$16.02 P/Share
|
|
Sep 09
2021
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
10,279
+3.49%
|
$133,627
$13.8 P/Share
|
|
Sep 08
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
8,000
-2.83%
|
$128,000
$16.0 P/Share
|
|
Sep 08
2021
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+2.76%
|
$104,000
$13.8 P/Share
|
|
Aug 31
2021
|
R Scott Greer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+14.26%
|
$540,000
$12.7 P/Share
|
|
Aug 24
2021
|
Robert Chess |
BUY
Bona fide gift
|
Indirect |
6,300
+50.0%
|
-
|
|
Aug 24
2021
|
Robert Chess |
SELL
Bona fide gift
|
Direct |
6,300
-2.25%
|
-
|
|
Aug 17
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
3,000
-1.23%
|
$39,000
$13.56 P/Share
|
|
Aug 16
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
7,867
-3.13%
|
$102,271
$13.83 P/Share
|
|
Aug 16
2021
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,192
-2.99%
|
$80,496
$13.83 P/Share
|
|
Aug 16
2021
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,339
-8.82%
|
$173,407
$13.83 P/Share
|
|
Aug 16
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
11,515
-2.64%
|
$149,695
$13.83 P/Share
|
|
Aug 16
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,910
-2.55%
|
$24,830
$13.83 P/Share
|
|
Aug 16
2021
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
7,662
-3.48%
|
$99,606
$13.83 P/Share
|
|
Jul 22
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
91
-0.03%
|
$1,456
$16.8 P/Share
|
|
Jul 22
2021
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
91
+0.03%
|
$1,183
$13.8 P/Share
|
|
Jul 21
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
3,524
-1.24%
|
$56,384
$16.81 P/Share
|
|
Jul 21
2021
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
3,524
+1.23%
|
$45,812
$13.8 P/Share
|
|
Jul 20
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
2,106
-0.75%
|
$33,696
$16.8 P/Share
|
|
Jul 20
2021
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
2,106
+0.74%
|
$27,378
$13.8 P/Share
|